Fruquintinib Patent Expiration
Fruquintinib is Used for the treatment of metastatic colorectal cancer that is resistant to multiple chemotherapies and targeted therapies. It was first introduced by Takeda Pharmaceuticals Usa Inc
Fruquintinib Patents
Given below is the list of patents protecting Fruquintinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fruzaqla | US10519142 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | Sep 07, 2035 | Takeda Pharms Usa |
| Fruzaqla | US11046674 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | Sep 07, 2035 | Takeda Pharms Usa |
| Fruzaqla | US7829574 | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases | May 09, 2028 | Takeda Pharms Usa |
| Fruzaqla | US8212033 | Use of substituted quinazoline compounds in treating angiogenesis-related diseases | May 09, 2028 | Takeda Pharms Usa |
Fruquintinib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List